Keapstone Therapeutics

Executive Summary

Keapstone Therapeutics is a private UK-based biotechnology company founded in 2021 that develops novel small molecules targeting the Keap1-Nrf2 interaction. By inhibiting this protein-protein interaction, Keapstone's therapeutics enable Nrf2 translocation to the nucleus, activating a broad panel of cytoprotective genes involved in redox balance, mitochondrial function, autophagy, and inflammation. This multi-pathway approach has potential applications in diseases driven by oxidative stress and chronic inflammation, including neurodegenerative disorders, metabolic diseases, and inflammatory conditions. The company is in preclinical development stages and has not disclosed specific lead candidates or funding rounds. Its differentiated mechanism offers a unique strategy to modulate multiple disease-modifying pathways with a single agent, though the early-stage profile carries significant development risk.

Upcoming Catalysts (preview)

• TBDLead Candidate Nomination and IND-Enabling Studies Initiation30% success
• TBDPreclinical Proof-of-Concept Data in Animal Models40% success
• TBDSeries A Financing or Strategic Partnership50% success